Sasaki K, Kantarjian HM, Morita K, Short NJ, et al. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 2021 Jun 17. doi: 10.1002/cncr.33655.
PMID: 34138471